Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 Combined with RFA for Small Hepatocellular Carcinoma
NCT03790059Unknown
- Sponsor
- Southwest Health System
- Start
- Oct 2016
- Primary completion
- Sep 2020
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Randomised trial of Oncorine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Southwest Health System. Primary endpoint: Tumor-free survival at 2 years. Status: unknown.
02
Drugs
Oncorine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03790059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790059.